Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

46.73 -1.64 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 987,960
Open 46.88
Bid (Size) 18.72 (2)
Ask (Size) 58.00 (2)
Prev. Close 48.37
Today's Range 45.76 - 48.10
52wk Range 24.00 - 58.38
Shares Outstanding 77,704,188
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review. 
Via Benzinga
Exposures Product Safety
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+1.9%
+1.9%
1 Month
-9.8%
-9.8%
3 Month
+1.9%
+1.9%
6 Month
+32.1%
+32.1%
1 Year
+61.1%
+61.1%

More News

Read More
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
Via Investor's Business Daily
Exposures Product Safety
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Via Benzinga
Earnings Preview For PTC Therapeutics
Via Benzinga
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
Via Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Via Investor's Business Daily
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
Via Benzinga
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
Via Benzinga
Exposures Product Safety
3 Top Stocks That Could Still Rocket Higher in 2024
Via The Motley Fool
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
Via Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
Via Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
Via Benzinga
Exposures Product Safety
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Via InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
Via Benzinga

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 46.73
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 04/03/25 04:00 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 3.63B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.